We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

32 hedge funds and large institutions have $41.9M invested in Xilio Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 32 → 32 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.25% less ownership

Funds ownership: 58.51% → 58.25% (-0.25%)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

82% less capital inflows, than outflows

Capital inflows: $46.1K | Capital outflows: $260K

Holders
32
Holders Change
–
Holders Change %
0%
% of All Funds
0.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
3
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
+$36.2K
2
Renaissance Technologies
Renaissance Technologies
New York
+$4.55K
3
Northern Trust
Northern Trust
Illinois
+$2.72K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$2.6K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$178K
2
Cannell Capital
Cannell Capital
Wyoming
-$54K
3
Millennium Management
Millennium Management
New York
-$11.7K
4
Morgan Stanley
Morgan Stanley
New York
-$10.7K
5
BlackRock
BlackRock
New York
-$5.44K

XLO Hedge Fund Activity: Q2 2023 in Review

32 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2023, worth a combined $41.9M — down 18% from $51M a quarter earlier.

Fund positioning in XLO was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 6 trimmed.

The largest buyer was Charles Schwab, opening a new position worth an estimated $36.2K. The largest seller was Citadel Advisors, cutting an estimated $178K.

  • 32 institutional investors held Xilio Therapeutics (XLO) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $41.9M of Xilio Therapeutics stock for Q2 2023, down 18% quarter-over-quarter.
  • 1 fund opened new Xilio Therapeutics positions in Q2 2023 and 1 closed out, a net change of 0 holders.
  • The largest Xilio Therapeutics buyer in Q2 2023 was Charles Schwab, an estimated $36.2K added.
  • The largest Xilio Therapeutics seller in Q2 2023 was Citadel Advisors, an estimated $178K sold.

Based on aggregated 13F filings for Q2 2023.